Adam Feuerstein's Biotech Blog

Adam Feuerstein's Biotech Blog - TheStreet

Adam Feuerstein

Adam Feuerstein investigates the highly-speculative world of biotech stocks, and helps biotech investors avoid losing money.

To participate in Adam's "Biotech Stock Mailbag," please send your questions or comments using this form.

To chat with Adam on Twitter, click here.

Biotech Blog

Investors once OK with waiting patiently for a Gilead rebound are growing frustrated, even angry, at the company's lack of progress.
8/31/16 7:27AM
The 18% response rate for fostamatinib in the Rigel phase III study was on the lower end of investor expectations.
8/30/16 7:44AM
The drugmaker says it will launch the product in 'several weeks' at a list price of $300 per two-park carton.
8/29/16 12:04PM
Nymox will not be successful in convincing the U.S. Food and Drug Administration (or its counterpart in Europe) to approve fexapotide to treat men with enlarged prostates.
8/26/16 2:23PM
An Amgen drug to treat secondary hyperparathyroidism was rejected by U.S. regulators Wednesday but the biotech company offered no public explanation for why the drug's marketing application was denied.
8/25/16 9:27AM
The Nasdaq Biotechnology Index fell 3.5% heading into Wednesday's close, with the loss triggered by a statement from Clinton's presidential campaign blasting Mylan for 'outrageous' pricing of the EpiPen.
8/24/16 3:44PM
Shares of biotech micro-cap Cyclacel Pharmaceuticals have doubled in price in the past 10 days. Call it the Lloyd Christmas effect.
8/22/16 12:36PM
Acquiring Medivation will strengthen Pfizer's oncology franchise, which has lost ground in recent years to some Big Pharma competitors.
8/22/16 7:07AM
TheStreet's Adam Feuerstein answers reader questions about biotech stocks.
8/12/16 7:01AM
The cancer immunotherapy company's cash position has plunged to the point where it may no longer be capable of paying its operating expenses.
8/11/16 10:41AM
A cancer immunotherapy shocker has Bristol-Myers Squibb tumbling and rival Merck soaring on Friday morning.
8/5/16 10:36AM
TheStreet's Adam Feuerstein answers reader questions about biotech stocks.
8/5/16 7:01AM
The big bounce in Biogen's valuation over the past month would likely bake in a good chunk of the upside premium that could come from any takeover offer.
8/3/16 7:01AM
The new deals signal a long-term commitment from two of the largest biotech companies to focus on cancer immunotherapy as a platform for future growth.
8/2/16 10:21AM
An experimental treatment for a rare, children's spine disorder developed by Ionis achieved the primary endpoint of a late-stage clinical trial, triggering Biogen to exercise a partnership option.
8/1/16 12:51PM
The negative study results from Seres are a setback for companies trying to harness the power of bacteria to treat diseases.
7/29/16 9:49AM
TheStreet's Adam Feuerstein answers reader questions about biotech stocks.
7/29/16 7:01AM
Celgene posted second-quarter earnings which exceeded analyst consensus expectations by a small margin but enough to raise guidance for the remainder of the year.
7/28/16 8:02AM
BMN 270 is one of the most important drugs in Biomarin's research pipeline and key driver of future revenue and earnings.
7/27/16 3:47PM
A small group of Alzheimer's patients treated with Anavex 2-73 are exhibiting signs of memory loss, faltering cognition and inability to take care of themselves over time.
7/27/16 2:38PM
A TauRx Therapeutics drug designed to dissolve tangles of a protein called tau in the brain failed to slow cognitive and functional declines of Alzheimer's patients compared with a control.
7/27/16 8:00AM
When your top line declines, it's harder to convince investors it's okay to wait years see if a partnership in an early-stage biotech company delivers a home-run drug.
7/26/16 10:34AM
Celgene will not seek approval for Revlimid as a maintenance therapy for patients with diffuse large B-cell lymphoma based on the lack of a survival benefit in a clinical trial.
7/25/16 5:06PM
Gilead's stock trades at a discount to other biotech peers because its drug research pipeline lacks the blockbusters needed to make up for slowing sales from its hepatitis C franchise.
7/25/16 4:20PM